Overview
Exploring Emerging Therapeutic Opportunities for Menopausal Women with Autoimmune Disease
Menopause Expert Perspectives
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Expert endocrinologist Ekta Kapoor, MBBS, and leading rheumatologist, Mehret Birru Talabi, MD, PhD, discuss the menopause experience for women with autoimmune conditions including the risks associated with hormone replacement therapy (HRT) in antiphospholipid (aPL)-positive patients, recommended management of vasomotor symptoms (VMS) with concomitant autoimmune diseases, and the potential with emerging neurokinin receptor antagonists in the management of VMS.
This educational activity is designed for OB/GYN, endocrinologists, rheumatologists, and internists, who manage women with autoimmune conditions during perimenopause.
This education is designed to provide clinicians information on the complexity and consequences of menopause in women with autoimmune diseases and up-to date guidance on available interventions to treat VMS in women for whom HRT is not recommended.
Upon completion of this activity, participants will be able to:
• Describe risks associated with HRT in aPL-positive patients
• Summarize guidance and unmet clinical needs for the management of menopause symptoms in women with different autoimmune diseases
• Discuss the therapeutic potential of emerging neurokinin receptor antagonists in managing VMS for women with autoimmune conditions
• Describe risks associated with HRT in aPL-positive patients
• Summarize guidance and unmet clinical needs for the management of menopause symptoms in women with different autoimmune diseases
• Discuss the therapeutic potential of emerging neurokinin receptor antagonists in managing VMS for women with autoimmune conditions
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Astellas.
On May 12, 2023, fezolinetant received FDA approval for the treatment of moderate to severe vasomotor symptoms caused by menopause.
Ekta Kapoor, MBBS
Associate Professor of Medicine
Mayo Clinic College of Medicine
Associate Director Women’s Health
Mayo Clinic
Rochester, MN
Associate Professor of Medicine
Mayo Clinic College of Medicine
Associate Director Women’s Health
Mayo Clinic
Rochester, MN
Mehret Birru Talabi, MD, PhD
Assistant Professor of Medicine
Associate Program Director, UPMC Rheumatology Fellowship
Division of Rheumatology and Clinical Immunology
Assistant Dean and Co-Director of Pitt/CMU Medical Science Training Program
University of Pittsburgh School of Medicine
Pittsburg, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Ekta Kapoor, MBBS
Sources of Funding for Grants/Research: Mithra Pharmaceuticals
Consulting Agreements: Astellas Pharmaceuticals, Mithra Pharmaceuticals, Womaness
Principal Investigator: Mithra Pharmaceuticals
Mehret Birru Talabi, MD, PhD
No financial relationships to disclosure
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational neurokinin receptor antagonists
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Karen Catino at kcatino@achlcme.org
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
